Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe

Biodel Inc. (Nasdaq: BIOD) announced that the Company has expanded its two ongoing pivotal Phase III clinical trials of VIAject(TM) into Europe. Clinical sites have been initiated in Germany and patient treatment has begun. “We are expanding VIAject(TM)’s pivotal Phase III trials into Europe to support our planned European registration of VIAject(TM),” stated Dr. Solomon S. Steiner, Chairman and CEO of Biodel. [click link for full article]

More: continued here

Filed under: Clinical Trials on September 25th, 2007